|
Martin Lehr, MA, says given the capital and intellectual capacity constraints within large pharmaceutical companies and start-ups, ISTs provide an important path to unlocking the therapeutic value of developmental and marketed drugs.
|
|
|
Olga Laskina, PhD, discusses visible particles and manufacturing defects of the packaging components as well as the impact these defects can have on container closure integrity and functional characteristics.
|
|
|
Due to the advantages of parenteral sustained-release drug delivery (also known as long-acting injectables, LAIs) different types of sustained-release injectable delivery systems have been….
|
|
|
William Small, PhD, and Arsalan Khan say drug degradation can have toxicological effects in many instances, and it is imperative that this mechanism be minimized as much as possible. The best solution to this is to ensure that appropriate ingredients, both high in quality and purity, are chosen and used throughout the entire drug product lifecycle.
|
|
|
Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.
|
|
|
|
|

For nearly 30 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Our package testing services evaluate the strength and integrity characteristics of a packaging system before and after, simulating the anticipated conditions that the system may undergo. This combination of simulation and evaluation is used to validate package compliance with ASTM, ISO, ISTA and other accepted industry standards. Click here for more.

Looking for an experienced and committed steriles CDMO? Look no further than Pii. Pii has a strong pedigree of scientific know-how and regulatory experience across a range of dosage forms, including capacity for aseptic fill-finish. Our commitment to this market and our capabilities have grown further with investment in a new, fully-robotic aseptic filling line. With expanded capacity for small to medium-batch production of commercial and clinical materials, we are eager to discuss your needs, so we can help advance your sterile product. Click here for more.
|